Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Letter to the editor       Open Access
Manali MukherjeeMelanie KjarsgaardKatherine RadfordChynna HuangRichard LeighDelbert R. DorscheidCatherine LemiereLouis-Philippe BouletSusan WasermanJames Martin and Parameswaran Nair Email authorView ORCID ID profile


Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demonstrated in asthmatics with persistent airway eosinophilia in a randomised controlled trial till date. From this double-blind, placebo-controlled, multi-centred, randomized parallel group design, we report that omalizumab is possibly inadequate to control sputum eosinophilia, and therefore may not have a steroid-sparing effect, especially in those maintained on oral corticosteroids daily. This needs to be confirmed or refuted in a larger trial, which may be a challenge with respect to recruitment, since there are currently three additional biologics available to prescribe.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Egg Allergy? Don't Let That Stop You From Getting Vaccinated
Interasma Top story: Marijuana Cannabis Allergy, see more
Interasma RT @Aller_MD: Top story: Marijuana Cannabis Allergy, see more
Interasma RT @Aller_MD: Decline in measles vaccination is causing a preventable global resurgence of the disease
Interasma RT @Aller_MD: Discovery may help explain why women get autoimmune diseases far more often than men

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA